Barchart Research What to Expect from SLN Earnings SLN Generated August 5, 2026 Current Price $11.24 EPS Estimate $$-0.32 Consensus Rating Moderate Buy Average Move 5.76% Silence Therapeutics reports tomorrow...
New analyses from the Phase 1 SANRECO study demonstrate potential improvements in PV symptoms and quality-of-life Follow-up data show substantial reductions in phlebotomy...
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led...
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence...
Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for topline results in August 2026
Topline results for Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for third quarter of 2026
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman,...
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in a fireside chat at...
SANRECO Phase 2 study of divesiran in polycythemia vera (PV) fully enrolled; topline results anticipated in 3Q 2026 Strong balance sheet and cash runway into 2028
